Otrivin, like other sympathomimetic agents, should be used with caution in patients showing a strong reaction to adrenergic substances, as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure.
Otrivin should be used with caution in: patients with hypertension, cardiovascular disease; patients with hyperthyroidism, diabetes mellitus, phaeochromocytoma; patients with prostatic hypertrophy; patients treated with monoamine oxidase inhibitors (MAOI) or who have received them in the last two weeks (see Interactions).
Like other topical vasoconstrictors, Otrivin should not be used for more than seven consecutive days: prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa.
Do not exceed the recommended dose, especially in children and in the elderly.
Effects on ability to drive and use machines: Otrivin has no or negligible influence on the ability to drive and use machines.